Top Decile Podcast: Genevieve LeMarchal

A lot of venture funds say they do healthcare. Very few have built the operational muscle to back companies before the science is de-risked. On this episode of the Top Decile Podcast, Genevieve LeMarchal of Suncoast Ventures explains why that gap is exactly where she has made her entire thesis, and how it produced a fund her LPs describe as top decile.

Watch The Full Episode Here:

LeMarchal came to venture after more than a decade as a serial entrepreneur, building and scaling companies across tech and consumer before she ever wrote a check. Along the way she logged over 10,000 hours in early-stage sales, marketing, and growth strategy, and coached well over a thousand founders. That operating foundation is what she brings to Suncoast, a seed-stage fund backing the next generation of healthcare startups, and it is why she is recognized as one of the most prolific early-stage investors in Southern California.

LeMarchal's starting point is a contrarian read on how capital actually behaves. "Investors should be backing things that are being overlooked, and we should be backing things that are being underpriced and are being underestimated," she says. What baffled her before she became an investor was that venture so often did the opposite, flocking to whatever was already crowded.

Healthcare, in her view, is the clearest example of a category that gets mislabeled and mispriced. It gets lumped into one bucket and stamped hard, capital-intensive, and slow, when the reality is more specific. The capital intensity shows up at different stages, and the thing a company has to overcome is simply different, not necessarily bigger. The scarcity is real. LeMarchal ran a quick analysis on how many US investors had backed even three healthcare deals. "We discovered that less than 10% of venture capital investors in the United States had invested in three deals in healthcare," she says. Without purpose-built expertise, she argues, most investors can only ever follow, and their economics show it.

Suncoast started by looking at digital health, health tech, and medical devices, staying out of therapeutics and life sciences for the most part. But LeMarchal is quick to say she is not really hunting a category. "I want to find companies that are solving the healthcare problems of our generation," she says. She contrasts that with West Coast moonshots that solve problems humanity does not have yet, where there is no buyer today. The problems of this generation, by contrast, are the ones health systems, plans, and institutions are buying right now. That focus has shown up in returns. Her first fund began producing DPI early, and she expects it could be returned by next year.

What separates Suncoast operationally is a capability most seed funds do not carry in-house. "We have built the integration layer between innovation and health institutions," LeMarchal says, spanning health policy, systems, payers, and provider networks, with specialists on staff rather than advisors on call. That extends into diligence. "We're actually doing a level of economic analysis and actuarial work in our due diligence," she says, using healthcare economics and outcomes research both to weed out companies that look great but will never win reimbursement, and to arm the ones that will. With one fund one portfolio company, that work let the team point to stronger economic data and help the founder reconfigure her Series A pricing. The approach is hands-on enough that, as LeMarchal notes, "a lot of my LPs will say we are PE like in many ways."

Suncoast reads less like a portfolio and more like a community, something LeMarchal says emerged from her own military-family upbringing of open arms and belonging. She has deliberately built a diverse team of people who have walked the walk in healthcare and startups, non-consensus thinkers who, in her words, don't take themselves too seriously. She is also clear-eyed about where humans add value in an AI-native firm: the role of a human is to form relationships and to see the non-obvious connections that AI won't pick out.

Asked where the next big winners hide, LeMarchal named three segments. First, health tech fintech, where she barely sees deal flow even as care shifts out of pocket and people need new ways to pay. Second, the coming disruption from scientific superintelligence models in biotech, a reason she has deliberately held back there. And third, the drum she beats constantly. "The last thing, of course, and I beat this drum all the time, is women's health," she says, pointing to standout portfolio performance she expects the business press to cover.

LeMarchal's advice to first-time managers is unsentimental. Get your life, health, and relationships ready to take the hit, because they will. And find your edge. "A VC fund that invests in companies is easily found. That's a commodity, nobody cares. You need to have something special, and that is where the gold is." For much of the early journey, she says, she was the fund, and it survived simply because she got up each day and kept going. For LPs who want healthcare exposure led by an operator who understands the economics, and for founders solving the health problems of this generation, Suncoast Ventures is building something purpose-built rather than opportunistic. Interested LPs and founders can connect with Genevieve and the Suncoast team through VC Lab and Decile Access.

Suncoast Ventures is a seed-stage, pre-Series A fund backing healthcare startups across digital health, health tech, and medical devices, largely outside of therapeutics and life sciences. Founded and led by Genevieve LeMarchal, a serial entrepreneur with over 10,000 hours in early-stage growth and a track record coaching more than a thousand founders, the firm pairs conviction investing with in-house health policy, economics, and outcomes-research capabilities.

Watch The Full Episode Here: https://www.youtube.com/watch?v=vp790KIrJUE